Company / Working Capital
NEKTAR THERAPEUTICS Working Capital History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$212.7M
FY2025
5-year range
$199.9M / $710.4M
FY2021-FY2025
Trend
+6.4%
vs FY2024
Sector context
#165 of 213
Health Care
What the data says
NEKTAR THERAPEUTICS's working capital of $213M is lower than 77% of companies in the Health Care sector (FY2025). Working Capital returned to growth in FY2025 after 6 years of decline, reaching $213M.
Based on SEC 10-K filings.
$213M in FY2025 with a 5-year CAGR of -26.9%.
Declined from $279M to $213M over the past 2 years.
Health Care sector context is included.
Working Capital over time
Growth rates
- 3-Year CAGR
- -23.6%
- 5-Year CAGR
- -26.9%
- 10-Year CAGR
- -
Sector benchmark
Bottom 23% in Health CareTop 77% of 213This company $212.7M Sector average $934.6M
▼
-77.2% below sector average
Key checks
Key Insights
- 5-year CAGR of -26.9%, indicating a declining trend.
- In FY2025, working capital increased 6.4% year-over-year.
- Ranks #165 out of 213 companies in the Health Care sector.
- Peak working capital was recorded in FY2018.
Company context
Key Data Points
- Altman Z-Score -11.97 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $212.7M | +6.4% |
| FY2024 | $199.9M | -28.5% |
| FY2023 | $279.4M | -41.5% |
| FY2022 | $477.8M | -32.7% |
| FY2021 | $710.4M | -30.5% |
| FY2020 | $1.0B | -4.3% |
| FY2019 | $1.1B | -21.2% |
| FY2018 | $1.4B | +400.9% |
| FY2017 | $270.7M | -23.5% |
| FY2016 | $354.0M | +22.6% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026